Susquehanna Portfolio Strategies’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$544K	Buy	+112,122	New	+$448K	0.01%	652

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Susquehanna Portfolio Strategies's ZNTL Position: Q2 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 112,122 shares worth $544K. The stake represents 0.01% of the portfolio and ranks #652 among its holdings.

114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Susquehanna Portfolio Strategies held 112,122 shares of Zentalis Pharmaceuticals worth $544K as of Q2 2026.
Zentalis Pharmaceuticals was a new Susquehanna Portfolio Strategies position in Q2 2026.
Zentalis Pharmaceuticals made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #652 holding.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.